Development of Orphan Vaccines: An Industry Perspective
1999
Challenges in Developing Orphan Vaccines
publication
Evidence: moderate
Author Information
Author(s): Jean Lang, Susan C. Wood
Primary Institution: Pasteur Merieux Connaught
Hypothesis
The development of vaccines for rare infectious diseases is hindered by various economic and regulatory challenges.
Conclusion
The development of orphan vaccines is complicated by limited market potential and high costs, requiring innovative strategies to enhance availability.
Supporting Evidence
- Vaccine development involves significant investment and is often prioritized based on market potential.
- Orphan vaccines face challenges due to limited demand and high development costs.
- The U.S. Orphan Drug Act provides incentives for developing drugs for rare diseases.
- Many orphan vaccines have not yet received final authorization despite being designated as orphan products.
- Public awareness and political support are crucial for the success of orphan vaccine initiatives.
Takeaway
Making vaccines for rare diseases is hard because they cost a lot to make and not many people need them, so companies often don't want to make them.
Limitations
The study discusses the economic and regulatory barriers to orphan vaccine development but does not provide specific data or case studies.
Want to read the original?
Access the complete publication on the publisher's website